Movatterモバイル変換

[0]ホーム
URL:

AU4012497A - Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin - Google Patents

Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin

Info

Publication number
AU4012497A
AU4012497AAU40124/97AAU4012497AAU4012497AAU 4012497 AAU4012497 AAU 4012497AAU 40124/97 AAU40124/97 AAU 40124/97AAU 4012497 AAU4012497 AAU 4012497AAU 4012497 AAU4012497 AAU 4012497A
Authority
AU
Australia
Prior art keywords
rapamycin
cyclosporin
treatment
pharmaceutical compositions
transplant rejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU40124/97A
Other versions
AU730781B2 (en
Inventor
Barbara Haeberlin
Armin Meinzer
Hendrik J. Schuurman
Gerhard Zenke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=26309775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU4012497(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9615942.1Aexternal-prioritypatent/GB9615942D0/en
Priority claimed from GBGB9705684.0Aexternal-prioritypatent/GB9705684D0/en
Application filed by Novartis AGfiledCriticalNovartis AG
Publication of AU4012497ApublicationCriticalpatent/AU4012497A/en
Application grantedgrantedCritical
Publication of AU730781B2publicationCriticalpatent/AU730781B2/en
Anticipated expirationlegal-statusCritical
Expiredlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
AU40124/97A1996-07-301997-07-29Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycinExpiredAU730781B2 (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
GB96159421996-07-30
GBGB9615942.1AGB9615942D0 (en)1996-07-301996-07-30Organic compounds
GBGB9705684.0AGB9705684D0 (en)1997-03-181997-03-18Organic compounds
GB97056841997-03-18
PCT/EP1997/004123WO1998004279A1 (en)1996-07-301997-07-29Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin

Publications (2)

Publication NumberPublication Date
AU4012497Atrue AU4012497A (en)1998-02-20
AU730781B2 AU730781B2 (en)2001-03-15

Family

ID=26309775

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU40124/97AExpiredAU730781B2 (en)1996-07-301997-07-29Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycin

Country Status (15)

CountryLink
US (2)US6239124B1 (en)
EP (2)EP0956034B1 (en)
JP (2)JP3942641B2 (en)
AT (2)ATE222502T1 (en)
AU (1)AU730781B2 (en)
CA (1)CA2261666C (en)
CY (1)CY2391B1 (en)
DE (2)DE69736750T2 (en)
DK (2)DK1208847T3 (en)
ES (2)ES2182112T3 (en)
HK (1)HK1023720A1 (en)
NZ (1)NZ333657A (en)
PT (2)PT956034E (en)
SI (1)SI1208847T1 (en)
WO (1)WO1998004279A1 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ES2152281T3 (en)*1993-09-282001-02-01Scherer Gmbh R P MANUFACTURE OF WHITE GELATINE CAPSULES.
US5858401A (en)*1996-01-221999-01-12Sidmak Laboratories, Inc.Pharmaceutical composition for cyclosporines
NZ333657A (en)*1996-07-302000-05-26Novartis AgA pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
US20030199425A1 (en)*1997-06-272003-10-23Desai Neil P.Compositions and methods for treatment of hyperplasia
US6890546B2 (en)*1998-09-242005-05-10Abbott LaboratoriesMedical devices containing rapamycin analogs
US20030129215A1 (en)*1998-09-242003-07-10T-Ram, Inc.Medical devices containing rapamycin analogs
GB9825632D0 (en)*1998-11-231999-01-13Novartis AgOrganic compounds
GB9826882D0 (en)*1998-12-071999-01-27Novartis AgOrganic compounds
US20020006901A1 (en)*1999-02-052002-01-17Aldo T. IaconoUse of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2000067773A2 (en)*1999-05-102000-11-16Novartis AgCombinations of immunosupressive agents for the treatment or prevention of graft rejections
CA2427569C (en)*2000-11-032010-07-27Matrix Therapeutics LimitedSelective glucocorticoid receptor agonists
US20020127263A1 (en)*2001-02-272002-09-12Wenda CarlylePeroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US8741378B1 (en)2001-06-272014-06-03Advanced Cardiovascular Systems, Inc.Methods of coating an implantable device
US6641611B2 (en)*2001-11-262003-11-04Swaminathan JayaramanTherapeutic coating for an intravascular implant
US20040137066A1 (en)*2001-11-262004-07-15Swaminathan JayaramanRationally designed therapeutic intravascular implant coating
US20080145402A1 (en)*2001-09-102008-06-19Abbott Cardiovascular Systems Inc.Medical Devices Containing Rapamycin Analogs
US20030054042A1 (en)*2001-09-142003-03-20Elaine LiversidgeStabilization of chemical compounds using nanoparticulate formulations
AU2002333098B2 (en)*2001-10-192006-03-16Isotechnika Pharma Inc.Novel cyclosporin analog microemulsion preconcentrates
JP2005514344A (en)*2001-10-252005-05-19アセロジエニクス・インコーポレイテツド Compounds and methods for transplant rejection therapy
US6939376B2 (en)*2001-11-052005-09-06Sun Biomedical, Ltd.Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en)*2002-04-242010-03-23Biosensors International Group, Ltd.Drug-delivery endovascular stent and method for treating restenosis
US7109169B2 (en)*2002-06-282006-09-19Hobai Ion AMethod for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
MXPA05000139A (en)2002-07-162005-04-11Biotica Tech LtdProduction of polyketides and other natural products.
KR101012605B1 (en)*2002-09-062011-02-10아보트 러보러터리즈 Medical device containing hydration inhibitor
AU2003272471B2 (en)*2002-09-182010-10-07Trustees Of The University Of PennsylvaniaMethod of inhibiting choroidal neovascularization
US8202530B2 (en)*2002-09-272012-06-19Advanced Cardiovascular Systems, Inc.Biocompatible coatings for stents
AR043504A1 (en)*2003-03-172005-08-03Novartis Ag PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7160867B2 (en)2003-05-162007-01-09Isotechnika, Inc.Rapamycin carbohydrate derivatives
BRPI0413927B8 (en)*2003-08-292021-05-25Lifecycle Pharma As pharmaceutical composition comprising tacrolimus, dosage form, use of the composition, and method for preparing the composition
KR20060085246A (en)2003-09-182006-07-26마커사이트, 인코포레이티드 Trans scleral delivery
EP1768662A2 (en)2004-06-242007-04-04Novartis Vaccines and Diagnostics, Inc.Small molecule immunopotentiators and assays for their detection
US8709469B2 (en)2004-06-302014-04-29Abbott Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en)2004-08-112004-09-15Biotica Tech LtdProduction of polyketides and other natural products
US8021849B2 (en)*2004-11-052011-09-20Siemens Healthcare Diagnostics Inc.Methods and kits for the determination of sirolimus in a sample
US8663639B2 (en)2005-02-092014-03-04Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
GB2438544A (en)2005-02-092007-11-28Cooper Internat CorpLiquid formulations for treatment of diseases or conditions
US20060257450A1 (en)*2005-03-212006-11-16Sreenivasu MudumbaDrug delivery systems for treatment of diseases or conditions
BRPI0607198A2 (en)*2005-02-152016-11-01Wyeth Corp composition, use of composition diseases treatment method, and pharmaceutical packaging
KR20190062506A (en)2005-02-182019-06-05아브락시스 바이오사이언스, 엘엘씨Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en)2005-02-182014-05-27Abraxis Bioscience, LlcCombinations and modes of administration of therapeutic agents and combination therapy
AU2006221774A1 (en)2005-03-112006-09-14Biotica Technology LimitedMedical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en)2005-03-112005-04-20Biotica Tech LtdNovel compounds
CA2603084A1 (en)2005-04-122006-10-19Elan Pharma International LimitedNanoparticulate and controlled release compositions comprising cyclosporine
US7189582B2 (en)*2005-04-272007-03-13Dade Behring Inc.Compositions and methods for detection of sirolimus
WO2006119130A2 (en)*2005-04-292006-11-09Atrium Medical CorporationDrug delivery coating for use with a medical device and methods of treating vascular injury
US20080020040A1 (en)*2006-07-182008-01-24Horizon Therapeutics, Inc.Unit dose form for administration of ibuprofen
US20080021078A1 (en)*2006-07-182008-01-24Horizon Therapeutics, Inc.Methods and medicaments for administration of ibuprofen
JP2009501801A (en)*2005-07-182009-01-22ホライゾン セラピューティクス， インコーポレイテッド Medicament containing ibuprofen and famotidine and its administration
US8067451B2 (en)2006-07-182011-11-29Horizon Pharma Usa, Inc.Methods and medicaments for administration of ibuprofen
EP2001438A2 (en)2006-02-092008-12-17Macusight, Inc.Stable formulations, and methods of their preparation and use
PL2001466T3 (en)2006-03-232016-06-30Santen Pharmaceutical Co LtdLow-dose rapamycin for the treatment of vascular permeability-related diseases
US8067033B2 (en)*2007-11-302011-11-29Horizon Pharma Usa, Inc.Stable compositions of famotidine and ibuprofen
WO2008027963A2 (en)*2006-08-312008-03-06Horizon Therapeutics, Inc.Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US8661630B2 (en)2008-05-212014-03-04Abbott Cardiovascular Systems Inc.Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
DE102008060549A1 (en)2008-12-042010-06-10MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Drug-peptide construct for extracellular accumulation
US11304960B2 (en)2009-01-082022-04-19Chandrashekar GiliyarSteroidal compositions
NZ602385A (en)2010-03-292014-08-29Abraxis Bioscience LlcMethods of treating cancer
MX369728B (en)2010-03-292019-11-20Abraxis Bioscience LlcMethods of enhancing drug delivery and effectiveness of therapeutic agents.
US8685433B2 (en)2010-03-312014-04-01Abbott Cardiovascular Systems Inc.Absorbable coating for implantable device
KR20190038684A (en)2010-06-042019-04-08아브락시스 바이오사이언스, 엘엘씨Methods of treatment of pancreatic cancer
US9034858B2 (en)2010-11-302015-05-19Lipocine Inc.High-strength testosterone undecanoate compositions
US20180153904A1 (en)2010-11-302018-06-07Lipocine Inc.High-strength testosterone undecanoate compositions
US9358241B2 (en)2010-11-302016-06-07Lipocine Inc.High-strength testosterone undecanoate compositions
US20120148675A1 (en)2010-12-102012-06-14Basawaraj ChickmathTestosterone undecanoate compositions
CA2825786A1 (en)*2011-01-312012-08-09Osaka UniversityExternally-used drug for treating skin disorder and method for producing same
EP2717884A1 (en)2011-06-062014-04-16Chevron Phillips Chemical Company LPUse of metallocene compounds for cancer treatment
GB201122305D0 (en)2011-12-232012-02-01Biotica Tech LtdNovel compound
US9220759B2 (en)2012-02-232015-12-29Abbott Cardiovascular Systems Inc.Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en)2012-03-302015-12-29Abbott Cardiovascular Systems Inc.Treatment of diabetic patients with a stent and locally administered adjunctive therapy
EP2705856A1 (en)2012-09-072014-03-12Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.Compounds for the treatment of neurodegenerative disorders
EP2948134B1 (en)2013-01-242020-03-04Palvella Therapeutics, Inc.Compositions for transdermal delivery of mtor inhibitors
JP6749239B2 (en)2013-09-242020-09-02ガイナー ライフ サイエンシズ，インク． Cell implant gas treatment system
US9498485B2 (en)2014-08-282016-11-22Lipocine Inc.Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)2014-08-282017-08-31Lipocine Inc.(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2017079736A1 (en)*2015-11-062017-05-11The Trustees Of Columbia University In The City Of New YorkExosomal protein profiling for detection of cardiac transplant rejection
MX2019005676A (en)2016-11-152019-09-10Giner Life Sciences IncPercutaneous gas diffusion device suitable for use with a subcutaneous implant.
CA3078723A1 (en)2016-11-282018-05-31Nachiappan ChidambaramOral testosterone undecanoate therapy
JP7108631B2 (en)2017-01-062022-07-28パルヴェラ セラピューティクス、インク． Anhydrous compositions of mTOR inhibitors and methods of use thereof
WO2018148508A1 (en)2017-02-102018-08-16Mount Tam Biotechnologies, Inc.Rapamycin analog
CN110831656A (en)2017-05-042020-02-21吉纳生命科学公司Robust implantable gas delivery devices and methods, systems, and devices including the same
WO2020010073A1 (en)2018-07-022020-01-09Palvella Therapeutics, Inc.ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
AU2019308326A1 (en)2018-07-202021-03-18Lipocine Inc.Liver disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4894366A (en)1984-12-031990-01-16Fujisawa Pharmaceutical Company, Ltd.Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en)1989-06-061992-03-31Roy CalneMethods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5286731A (en)1991-09-171994-02-15American Home Products CorporationMethod of treating immunoinflammatory bowel disease
US5286730A (en)*1991-09-171994-02-15American Home Products CorporationMethod of treating immunoinflammatory disease
DK0562853T3 (en)1992-03-271996-07-01American Home Prod 29-Demethoxyrapamycin to induce immunosuppression
GB9221220D0 (en)1992-10-091992-11-25Sandoz AgOrganic componds
GB2278780B (en)1993-05-271998-10-14Sandoz LtdMacrolide formulations
GB9601120D0 (en)*1996-01-191996-03-20Sandoz LtdOrganic compounds
GB9606452D0 (en)1996-03-271996-06-05Sandoz LtdOrganic compounds
NZ333657A (en)*1996-07-302000-05-26Novartis AgA pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
WO2000067773A2 (en)*1999-05-102000-11-16Novartis AgCombinations of immunosupressive agents for the treatment or prevention of graft rejections

Also Published As

Publication numberPublication date
NZ333657A (en)2000-05-26
JP2004210767A (en)2004-07-29
EP0956034B1 (en)2002-08-21
DK1208847T3 (en)2007-01-08
ATE340586T1 (en)2006-10-15
PT1208847E (en)2007-07-24
ES2270948T3 (en)2007-04-16
JP4149905B2 (en)2008-09-17
HK1023720A1 (en)2000-09-22
DK0956034T3 (en)2002-12-16
US6455518B2 (en)2002-09-24
DE69714861D1 (en)2002-09-26
CA2261666A1 (en)1998-02-05
EP1208847B8 (en)2007-02-14
CY2391B1 (en)2004-09-10
PT956034E (en)2002-12-31
EP1208847A2 (en)2002-05-29
DE69736750T2 (en)2007-08-16
EP0956034A1 (en)1999-11-17
US6239124B1 (en)2001-05-29
EP1208847B1 (en)2006-09-27
US20010008888A1 (en)2001-07-19
JP2000505806A (en)2000-05-16
DE69736750D1 (en)2006-11-09
EP1208847A3 (en)2002-06-12
ES2182112T3 (en)2003-03-01
ATE222502T1 (en)2002-09-15
JP3942641B2 (en)2007-07-11
AU730781B2 (en)2001-03-15
SI1208847T1 (en)2007-06-30
DE69714861T2 (en)2003-05-22
CA2261666C (en)2010-09-14
WO1998004279A1 (en)1998-02-05

Similar Documents

PublicationPublication DateTitle
AU4012497A (en)Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
AU638253B2 (en)Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
NZ310767A (en)Use of an immunosuppressive or non-immunosuppressive pipecolic acid derivative for treating neurological disorders
AU6883994A (en)Pharmaceutical composition
IL122905A (en)Pharmaceutical compositions in the form of a solid dispersion comprising a rapamycin
IL166824A0 (en)Oral formulations
AU1574695A (en)Intra-ocular lens arrangement for correcting astigmatism
AU4121597A (en)Cross-linked copolymers based on polycarboxylic polymers
AU3342895A (en)Combination preparation, containing cyclosporin a or fk506 or rapamycin and a xanthine derivative
CA2257803A1 (en)Non immunosuppressive antifungal rapalogs
AU4565000A (en)Organic compounds
SI0956034T1 (en)Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin
CA2543665A1 (en)Cci-779 for treating mantle cell lymphoma
IL81508A (en)Phytopathogenic antibiotic compositions comprising rifamycin derivatives
WO2001026605A3 (en)Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor
AU7325194A (en)Compact golf facility and method for eliminating handicap scoring

Legal Events

DateCodeTitleDescription
FGALetters patent sealed or granted (standard patent)
[8]ページ先頭
©2009-2025 Movatter.jp